Monday, June 7, 2010 | Oncolink

Oncolink Features

Find My Cancer Drug

A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome Presenter: K. Ang, University of Texas M. D. Anderson Cancer Center, Houston, TX Background Accelerated fractionation of radiotherapy and concurrent chemoradiotherapy have both been shown to improve outcomes in locally advanced HNC patients...
Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003 Authors: M. L. Gillison, The Ohio State University, Columbus, OH Background There is a growing body of evidence that Human Papillomavirus (HPV) infection plays an important role in the pathogenesis of a subset of head and neck squamous cell...
Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study Presenter: A. M. Termuhlen, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, OH Background Wilms tumor (WT) is the most common pediatric abdominal tumor. The development of more effective therapy...
Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial Presenter: J. S. Temel, Massachusetts General Hospital, Boston, MA. Background Patients with metastatic NSCLC often have a high symptom burden from the time of initial diagnosis, which greatly affects their quality of life. These patients...
Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC) Presenter: J. Y. Lai, PhD; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada Background Cervical cancer is a major cause of cancer morbidity and mortality worldwide, with an estimated 11,270 new cases in the...
Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial Presenter: G. Pfeiler, MD, Medical University of Vienna Background In hormone receptor positive breast cancers, drugs such as Tamoxifen and aromatase inhibitors decrease the production of estrogens, and have been shown to lead to...
Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer Presenter: K. S. Hughes, CALBG, ECOG, RTOG, Massachusetts General Hospital, Boston, MA Background The Early Breast Cancer Trialists’ Collaborative Group Overview (Lancet, 2005), showed that radiation therapy (RT) after breast-conserving...
Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN) Presenter: K. J. Harrington, Royal Marsden Hospital, UK Background Lapatinib is an oral small-molecule dual tyrosine kinase (TK) inhibitor of EGFR (epidermal growth factor receptor), which targets Her2 receptors. This drug has...
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy Presenter: S. Lee, University College Hospital/UCL Cancer Institute, London, United KingdomBackground Patients with poor performance status (PS) represent 30-50% of those presenting with advanced (Stage IIIB/IV) NSCLC, and are under-studied. ...